The short version
9 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Doxil
doxorubicin hydrochloride · DOXORUBICIN HYDROCHLORIDE 2 mg/mL · Injection, Suspension, Liposomal · Intravenous · Baxter Healthcare Corporation
NDC 00338-9665-01 · 1 VIAL, SINGLE-DOSE in 1 CARTON / 25 mL in 1 VIAL, SINGLE-DOSE · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$1,684.00
Reported to Texas DSHS · 2026 annual filing · Baxter Healthcare Corporation
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 10 MG
$116.605
HCPCS Q2050 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$8,458
11 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Eurofins Biolab SrlItalyanalysis
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA050718
- TE code
- AB
- Approval date
- Nov 17, 1995
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of doxorubicin hydrochloride (Injection, Suspension, Liposomal)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Alembic Pharmaceuticals Inc. | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Baxter Healthcare Company | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| BluePoint Laboratories | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Dr. Reddy's Laboratories Inc. | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| Lupin Pharmaceuticals, Inc. | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 3, 2026 |
| GlaxoSmithKline Manufacturing SpA | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Sagent Pharmaceuticals | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Alembic Pharmaceuticals Limited | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Aug 31, 2026 |
| Baxter Healthcare Corporation | DOXORUBICIN HYDROCHLORIDE 2 mg/mL | Jul 15, 2026 | Aug 28, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Doxil — NDC 00338-9665-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00338966501.
Free to cite with attribution — see how the data is put together.